Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy

Cancer Res (2022) 82 (12_Supplement): CT013.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Durable Responses in Patients With Advanced Cholangiocarcinoma on Sequential Dual-agent Immunotherapy After Progressing on Single-agent Immunotherapy

Dalia Kaakour
Garo Hagopian
Sonia Lee
Fa Chyi Lee

American Journal of Clinical Oncology (2022) 45 (10): 410.

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Jason Chesney
Karl D Lewis
Harriet Kluger
Omid Hamid
Eric Whitman
Sajeve Thomas
Martin Wermke
Mike Cusnir
Evidio Domingo-Musibay
Giao Q Phan
John M Kirkwood
Jessica C Hassel
Marlana Orloff
James Larkin
Jeffrey Weber
Andrew J S Furness
Nikhil I Khushalani
Theresa Medina
Michael E Egger
Friedrich Graf Finckenstein
Madan Jagasia
Parameswaran Hari
Giri Sulur
Wen Shi
Xiao Wu
Amod Sarnaik

Journal for ImmunoTherapy of Cancer (2022) 10 (12): e005755.